1 min read
Add as a preferred source on Google

FDA Approves Roche’s Wilserdly Oral Breast Cancer Therapy

The approval is the first of two U.S. regulatory decisions expected this year for the oral therapy.

A white tablet rests at the edge of a ceramic groove / TokenPost.ai
A white tablet rests at the edge of a ceramic groove / TokenPost.ai

Roche announced that the U.S. Food and Drug Administration (FDA) approved Wilserdly (giredestrant), the company’s oral breast cancer therapy.

The approval is the first of two U.S. regulatory decisions expected this year for the therapy.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…